

In the Claims:

Claims 1-59 (Cancelled)

BEST AVAILABLE COPY

60. (Currently Amended): An isolated polypeptide comprising a member selected from the group consisting of

- (a) the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4;
- (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 contiguous amino acids that matches an aligned contiguous segment of SEQ ID NO:2 or SEQ ID NO:4;

wherein the immunogenic fragment isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the isolated to a polypeptide having the sequence of SEQ ID NO:2 or SEQ ID NO:4.

61. (Previously Presented): The isolated polypeptide of claim 60, wherein the polypeptide is according to (a).

62. (Previously Presented): The isolated polypeptide of claim 60, wherein the polypeptide is according to (b).

63. (Currently Amended): The isolated polypeptide of claim 60, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.

64. (Previously Presented): The isolated polypeptide of claim 60, wherein the isolated polypeptide consists of SEQ ID NO:2 or SEQ ID NO:4.

BEST AVAILABLE COPY

Serial No.: 09/700,293
Docket No.: BM45321

65. (Previously Presented): A fusion protein comprising the isolated polypeptide of Claim

60

66. (Previously Presented): An immunogenic composition comprising the polypeptide of
Claim 60 and a pharmaceutically acceptable carrier.

67. (Previously Presented): The immunogenic composition of Claim 66, wherein the
immunogenic composition further comprises at least one other *Neisseria Meningitidis* antigen.

68. (New): The isolated polypeptide of Claim 60, wherein the isolated polypeptide is a
recombinant polypeptide.

69. (New): The isolated polypeptide of Claim 61, wherein the isolated polypeptide is a
recombinant polypeptide.

70. (New): The isolated polypeptide of Claim 62, wherein the isolated polypeptide is a
recombinant polypeptide.

71. (New): An immunogenic composition comprising the isolated polypeptide of claim 61.

72. (New): An immunogenic composition comprising the isolated polypeptide of claim 62.

73. (New): A fusion protein comprising the isolated polypeptide of claim 61.

74. (New): A fusion protein comprising the isolated polypeptide of claim 62.